A

AcelRx Pharmaceuticals Inc
F:R5X

Watchlist Manager
AcelRx Pharmaceuticals Inc
F:R5X
Watchlist
Price: 2.106 EUR 9.74%
Market Cap: 310.3m EUR

AcelRx Pharmaceuticals Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

AcelRx Pharmaceuticals Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
A
AcelRx Pharmaceuticals Inc
F:R5X
Net Income (Common)
-$26.5m
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
6%
Johnson & Johnson
NYSE:JNJ
Net Income (Common)
$25.1B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
5%
Bristol-Myers Squibb Co
NYSE:BMY
Net Income (Common)
$6B
CAGR 3-Years
-3%
CAGR 5-Years
N/A
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Net Income (Common)
$9.8B
CAGR 3-Years
-31%
CAGR 5-Years
4%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Net Income (Common)
$19B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
6%
Eli Lilly and Co
NYSE:LLY
Net Income (Common)
$18.4B
CAGR 3-Years
45%
CAGR 5-Years
27%
CAGR 10-Years
23%
No Stocks Found

AcelRx Pharmaceuticals Inc
Glance View

Market Cap
310.3m EUR
Industry
Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in Hayward, California and currently employs 43 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.

R5X Intrinsic Value
Not Available
A

See Also

What is AcelRx Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-26.5m USD

Based on the financial report for Sep 30, 2023, AcelRx Pharmaceuticals Inc's Net Income (Common) amounts to -26.5m USD.

What is AcelRx Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
6%

The average annual Net Income (Common) growth rates for AcelRx Pharmaceuticals Inc have been 17% over the past three years , 10% over the past five years , and 6% over the past ten years .

Back to Top